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Abstract
Plasmodium falciparum, the Apicomplexan parasite that is responsible for the most lethal forms of
human malaria, is exposed to radically different environments and stress factors during its complex
lifecycle. In any organism, Hsp70 chaperones are typically associated with tolerance to stress. We
therefore reasoned that inhibition of P. falciparum Hsp70 chaperones would adversely affect parasite
homeostasis. To test this hypothesis, we measured whether pyrimidinone-amides, a new class of
Hsp70 modulators, could inhibit the replication of the pathogenic P. falciparum stages in human red
blood cells. Nine compounds with IC50 values from 30 nM to 1.6 μM were identified. Each compound
also altered the ATPase activity of purified P. falciparum Hsp70 in single-turnover assays, although
higher concentrations of agents were required than was necessary to inhibit P. falciparum replication.
Varying effects of these compounds on Hsp70s from other organisms were also observed. Together,
our data indicate that pyrimidinone-amides constitute a novel class of anti-malarial agents.
Keywords
Molecular chaperone; Hsp70; Hsp40; J domain; ATPase; Pyrimidinone
1. Introduction
Plasmodium falciparum malaria kills ~3000 people each day, mostly children in sub-Saharan
Africa. Several anti-malarial agents are available that–in principle–could prevent this disease.
Unfortunately, the use of some of these agents is compromised by parasite resistance, high
cost, and/or dangerous or unpleasant side-effects. Also, some therapies are combinations of
existing drugs (e.g., artemether-lumefantrine, dihydroartemisinin-piperaquine, or artesunate-
amodiaquine)1,2 that depend on the inability of the parasite to become resistant to artemisinin
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derivatives. Therefore, continued efforts to identify novel compounds that kill P. falciparum
are critical.
The P. falciparum genome encodes six Hsp70 and forty-three Hsp40 molecular chaperones.
3,4 Hsp70 molecular chaperones couple the hydrolysis of ATP with the binding and release of
polypeptide substrates and play vital roles in protein folding, degradation and transport.5
Hsp40s interact with Hsp70 through a conserved, four helix-bundle known as the ‘J domain’.
J domain interactions enhance Hsp70 ATPase activity; similar to Hsp70s, many Hsp40s are
also polypeptide-binding proteins.6 Hsp70s and Hsp40s can constitute a significant amount of
total cellular protein, a percentage that rises when cells are stressed (hence the ‘heat shock
protein’ nomenclature).7
There are several reasons why P. falciparum might require the function of Hsp70 and Hsp40
chaperones. First, this parasite, like other members of the Apicomplexa, contains several endo-
membrane systems.8 Because Hsp70-Hsp40 pairs engineer protein transport across membranes
and are essential for membrane integrity, 9 each internal membrane might require its own set
of chaperones. In support of this hypothesis, it was recently shown that a J domain-containing
protein in P. falciparum (PF10_0381) is required for ‘knob’ formation, a structure that helps
the presentation of PfEMP1 proteins on the red blood cell surface; this, in turn, leads to the
binding of parasitized red blood cells to the vascular endothelium. 10 Second, the parasite is
exposed to radically different environments during its life cycle. It is capable of thriving in the
mosquito, in the host liver, and in the highly oxidizing environment of the red blood cell.11
Thus, Hsp70s and Hsp40s might be necessary to offset cellular stresses that are encountered
during the P. falciparum life cycle. Third, P. falciparum exhibits sudden bursts of protein
synthesis as it enters the trophozoite stage that marks the initiation of several rounds of
intracellular division. Molecular chaperones help retain newly synthesized polypeptides in
soluble conformations and facilitate folding.12 For example, an inhibitor of the Hsp90
chaperone, which is required for folding select cellular proteins, was shown to inhibit the ‘ring’
to trophozoite transition.13 Finally, it appears that the parasite contains extensive chaperone
networks that are involved in a multitude of cellular activities.14 Based on these data, P.
falciparum viability should be exceptionally sensitive to Hsp70-Hsp40 inhibition. Indeed,
parasite growth is inhibited by 15-deoxyspergualin,15,16 a non-specific chaperone modulator
that binds to Hsp70 and to Hsp90 with a KD of ~5 μM.17
We previously reported the synthesis and characterization of pyrimidinone-peptoid hybrid
molecules that modulate Hsp70 activity in vitro and that, in some cases, prevent cancer cell
proliferation. 18–21 These data indicate that specific Hsp70 modulators can be identified and
that at least a sub-group of these compounds is membrane-permeable, as evidenced by their
activity in a cellular assay. To test whether molecules in this class also compromise P.
falciparum replication, we screened a small collection of pyrimidinones and identified nine
compounds that exhibited potent effects on parasite metabolism. Some of these compounds
inhibited P. falciparum viability with similar potencies to some established anti-malarial drugs.
22 We also developed new purification schemes for Hsp70 proteins from Homo sapiens and
P. falciparum and compared the effects of these compounds on the ATPase activities of the
human, yeast, and parasite chaperones. Together, our data support the continued investigation
of pyrimidinones as antimalarial agents.
2. Results and discussion
To assess whether pyrimidinones inhibit P. falciparum growth, we examined the effects of 157
compounds in this class and related Biginelli and Ugi multicomponent condensation-derived
compounds on the uptake of [3H]hypoxanthine into infected human erythrocytes. The
hypoxanthine assay provides a rapid, quantifiable read-out of parasite viability, and the
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compounds assayed included several recently described agents,18 as well as precursors and
structurally related analogs.
The impact of JAB75 (see Section 3) on [3H]hypoxanthine up-take is shown in Figure 1. In
this and all other assays, we used the chloroquine (CQ)-resistant Dd2 clone and employed CQ
as an internal control because CQ is known to inhibit Dd2 with an IC50 value of ~0.2 μM.23,
24 In this experiment, the IC50 for JAB75 was calculated to be ~0.3 μM (Table 1, second
column) and the IC50 for CQ was 0.19 μM (data not shown). From our initial analysis of 157
compounds, we identified nine molecules (Fig. 2; see Section 3) with IC50 values between 30
nM and 1.6 μM (Table 1, second column).
To ensure that the compounds were not generally cytotoxic, we also determined the 50%
growth inhibitory concentrations (GI50) for each of these nine agents in two human cell lines,
HepG2 hepatocellular carcinoma cells and WI-38 embryonic diploid lung cells, as previously
described.18 Based on this analysis, all GI50 values in these cells were >10 μM, which is well
above the concentration needed to inhibit P. falciparum growth (Table 1). As a control for this
experiment, we found that the GI50 values for paclitaxel in HepG2 and WI-38 cells were 1.0
± 0.6 nM and 13.7 ± 0.2 nM, respectively (data not shown).
We previously showed that a subset of pyrimidinones inhibit the activity of Hsp70.18,19
Therefore, we next assessed the effects of the nine compounds on Hsp70 ATPase activity. We
first examined the ability of each pyrimidinone to modulate the ATP hydrolytic rate of a
purified yeast Hsp70, Ssa1, as previously published.18–20 In addition, we wished to compare
the effects of these agents on human and P. falciparum Hsp70. The three chaperones are 71–
74% identical to one another at the amino acid level and, not surprisingly, Hsp70s from different
species have been reported to substitute functionally for one another. For example, the growth
of bacteria containing a mutation in the gene encoding DnaK, the Hsp70 homolog, can be
rescued at high temperature by expression of a P. falciparum Hsp70.25 One might also envision,
however, that a specific inhibitor could selectively target the P. falciparum chaperone but have
no effect on Hsp70s from different species.
To compare the effects of the lead compounds on the ATPase activities of the Hsp70s, we first
modified purification schemes for both the H. sapiens and P. falciparum chaperones (see
Section 3). The peak fractions from the P. falciparum Hsp70 purification are shown Figure
3A, and the single-turnover ATPase activities of the enzyme in the absence and presence of a
J domain chimera (see below) are shown in Figure 3B.
Next, each of the nine compounds was incubated with the P. falciparum, yeast and human
chaperones, and steady-state ATPase assays were performed. The results presented in Table
1, columns 3–5, indicate that the compounds display a range of activities and alter the activities
of each chaperone distinctly. For example, JAB75, MAL2-61, and MAL2-215 reduced the rate
of ATP hydrolysis by the human enzyme by 30%, but had no effect or stimulated the activities
of the parasite and yeast enzymes. In contrast, MAL2-39 compromised the ATPase activities
of all three enzymes, but mainly HsHsp70. MAL3-39 inhibited all enzymes to a very similar
extent. Perhaps most intriguing, DMT2264 affected the ATPase activity of P. falciparum
Hsp70 significantly more than Ssa1 and HsHsp70. These data indicate that the pyrimidinones
can be classified based on their in vitro effects on Hsp70s from different species. Nevertheless,
it is important to note that these analyses were performed at a final concentration of 300 μM
in order to maximize the effects. We also selected this concentration because the action of
pyrimidinones was first studied under these conditions;18 however, when used at
concentrations that inhibited P. falciparum replication (Table 1), the steady-state ATPase
activity of Hsp70 was unaltered, suggesting the possibility of secondary targets or other issues
related to compound metabolism or accumulation (see below).
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The cellular activity of Hsp70 most often requires interaction with J domain-containing Hsp40
partners.5,6 In fact, one of our most potent pyrimidinone-based inhibitors of breast cancer cell
proliferation has no effect on endogenous ATPase activity but compromises the ability of a J
domain-containing co-chaperone to enhance ATP hydrolysis.19,21 Therefore, it was possible
that the compounds might have greater effects on the J domain-stimulated ATPase activity of
the Hsp70s. Because the purification of a P. falciparum Hsp40 has not been reported, we instead
chose to use a chimeric protein that contains the J domain from Hlj1, a yeast Hsp40, fused to
glutathione-S-transferase.26 Recent work indicates that the chimera interacts promiscuously
with a variety of Hsp70s and augments their ATPase activities.36 For comparison, we also used
a full-length ‘type-I’ Hsp40 co-chaperone from yeast, Ydj1.
We added each of the nine P. falciparum inhibitors in single-turnover ATPase reactions
containing either the parasite (PfHsp70) or yeast Hsp70 (Ssa1) in the presence or absence of
the Hlj1 chimera and Ydj1 (see Table 2). Furthermore, the activity of human Hsp70 in the
presence or absence of Ydj1 and one of its known Hsp40 partners, Hdj1, was examined in the
presence or absence of each pyrimidinone. We chose to use single-turnover conditions for this
analysis because the level of J domain-mediated stimulation of Hsp70 ATPase activity is
significantly greater for single-turnover assays as compared to steady-state assays (see, e.g.,
Fig. 3B). Furthermore, the effects of compounds on enzyme kCAT values can specifically be
monitored and the fold change measured. As shown in Table 2, these nine compounds exhibited
a range of effects. First, relatively subtle changes were observed when the effects of the
compounds were examined in the presence of the J domain protein. For example, a <50%
decrease (in the presence of MAL2-213 or DMT2264) and a ~40% increase (in the presence
of MAL2-61 or MAL3-39) was measured when the J domain was added into the assay in the
presence of these chemicals (Table 2, ‘fold change PfHsp70 kCAT + Hlj1’). In contrast, two of
the compounds induced a potent ‘burst’ of ATP hydrolysis in the single-turnover assay in the
absence of a J domain (‘fold change PfHsp70 kCAT’): Based on a fit of the data to a single
exponential, MAL2-39 and MAL2-61 enhanced P. falciparum Hsp70 ATPase activity by 7.2
and 6.5-fold, respectively. Each of the other compounds also enhanced ATP hydrolysis to
varying extents, an effect that has been previously noted for certain other pyrimidinones.18,
19 Because the cycle of Hsp70 ATP binding/hydrolysis is coupled with substrate binding and
release, altered rates of endogenous or J domain-stimulated ATP hydrolysis will
correspondingly alter the efficacy of substrate binding. Therefore, enhanced rates of ATP
hydrolysis can lead to defects in the ability of Hsp70s to act as a molecular chaperone, especially
under stress conditions.27,28 Moreover, recent data confirm that the individual chaperone
cycles and conformations have been tailored to match the folding of specific substrates.29 In
the future, it will be important to examine whether these agents affect the binding of known
Hsp70 substrates. Moreover, it is critical to note that effects on ATPase activity in steady-state
assays may result from alterations in any one of a number of steps in the hydrolytic cycle,
including the kCAT, ATP binding, and inorganic phosphate and/or ADP release.
An examination of the endogenous and J domain-stimulated ATPase activities of the yeast
enzyme in the presence or absence of the compounds yielded quite different results (Table 2,
‘fold change Ssa1 kCAT’ and ‘fold change Ssa1 kCAT + Hlj1’). We found that MAL2-215
exerted significant effects on both the endogenous and J domain-stimulated activity of Ssa1,
but the compounds with the greatest impact on the P. falciparum enzyme (e.g., MAL2-39,
MAL2-61, and MAL2-213) only modestly altered the activity of the yeast enzyme. Notably,
the strongest effects of each pyrimidinone were observed when the activity of the human
enzyme was examined in the presence of its partner, Hdj1. At this point, the substructure
features that mediate these distinct phenomena remain to be elucidated. Our data nevertheless
indicate that the continued examination of pyrimidinones with diverse Hsp70s will prove
worthwhile, especially if a specific binding site on the chaperone for this class of modulators
can be identified. Efforts toward this goal are underway.
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It is important to note that the relative effects of the compounds on the endogenous or J domain-
stimulated P. falciparum ATPase activities do not correlate with the IC50 values in the [3H]
hypoxanthine uptake assay (compare Table 1 and Table 2). There are several explanations for
this fact. First, it is possible that some compounds have secondary cellular targets, which may
enhance the antimalarial effects. Second, some of the compounds may be metabolized when
added to the infected erythrocytes to produce derivatives that may be more or less potent,
depending on the nature of the modification. Third, the less potent agents in the [3H]
hypoxanthine uptake assay might be actively excluded from cells due to the action of multi-
drug transporters or other gene products that are known to mediate drug resistance in this
parasite. 30 Assays with radiolabeled or fluorescently labeled compounds will help clarify this
possibility by enabling measurements of compound accumulation in the parasite; however,
these results are not yet available. Fourth, the bonafide Hsp70 that is a target of the active
compounds may be any one of the other five Hsp70s that are encoded by the P. falciparum
genome. It is striking how distinctly some compounds affect the activities of the yeast Ssa1
and human proteins and the P. falciparum Hsp70 utilized in this study (PfHsp70-1; PF08_0054)
even though these proteins are >70% identical. Because Hsp70-1 and the mitochondrial Hsp70
in P. falciparum (PfHsp70-3; PF11_0351) are only 48% identical, the compounds are also
expected to exhibit distinct effects on parasitic Hsp70s. The problem of identifying the target
(s) of these compounds could, in principle, be rectified by the purification of each of the six
P. falciparum Hsp70s and 43 P. falciparum J proteins so that each combination could be tested
in ATPase assays in the presence of the modulators. A streamlined approach would be to
prepare activated, affinity tagged derivatives of our novel P. falciparum inhibitors and then
identify potential cellular target(s) using an unbiased screen. This experimental regimen would
ideally isolate the ‘correct’ Hsp70 and/or Hsp40 chaperone target(s).
We note structural trends that relate to potency in the P. falciparum replication assay.
Specifically, there are several common and distinct features amongst the identified inhibitors
depicted in Figure 2. For example, all nine compounds share an ester pyrimidine core,
substituted at C-4, and eight of the nine are alkylated at N1. Among the compounds, DMT3024,
DMT2264, and MAL3-39 are structurally closely related. They share a benzyl ester pyrimidine
core that is substituted at C-4 with an arene moiety, and an N-alkylated amide side chain that
is attached via a 3–5 carbon linker. They differ in their side chain lipophilicity and in the
presence of the morpholine moiety on DMT3024 and MAL3-39, which is absent in DMT2264.
The most potent compounds, MAL2-215 and MAL2-213, have a slightly different ester
substitution on the pyrimidine core, as well as a distinct tetrasubstituted pyrrole side chain.
This tetrasubstituted pyrrole appears to be an important determinant of potency because
modifications in ester identity (Bn vs Et), N1 linker length (C-4 vs C-6), and C-4 aryl
substitution (Ph vs NO2) do not appear to affect activity. Finally, MAL2-61, MAL2-39, and
MAL2-29 are truncated derivatives that still have the signature pyrimidine heterocycles but a
minimal N1 side chain substituent lacking an amide function, i.e. H or Bn (JAB75), butyl
(MAL2-39), and hexanoic acid (MAL2-29).
In summary, we describe the discovery of a novel class of anti-malarial agents. In the future,
second-generation chemical libraries of these pyrimidinone sub-classes should be analyzed for
their effects on P. falciparum, but already we have identified compounds that have equal or
greater potency in the [3H]hypoxanthine uptake assay as established antimalarial agents and
that are synthetically readily modified.31 Based on the success of our initial efforts, reported
herein, we are confident that compounds with greater potencies and improved pharmacological
properties are within reach.
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3. Experimental
3.1. Synthesis of compounds using in this study
The synthesis of MAL3-39 and MAL2-215,19 DMT3024,18 and DMT226431 has previously
been reported. The following compounds were synthesized as described.
3.1.1. Synthesis of MAL2-29—TFA (50 μL) was added to a mixture of 6-ureiadohexanoic
acid (100 mg, 0.57 mmol), 3-nitrobenzaldehyde (73 mg, 0.48 mmol), and ethylacetate (61
μL, 0.48 mmol) in dichloroethane (3 mL), and the resulting mixture was heated to reflux under
N2 for 12 h. Next, dichloroethane was removed in vacuo, and the residue was stirred in Et2O,
filtered, and washed with hexane/acetone to afford UPCMLD00WMAL2-29 (128.0 mg, 53%)
as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 11.96 (s, 1H), 8.12 (d, 1H, J = 3.8 Hz),
8.06 (s, 1H), 7.65–7.63 (m, 2H), 5.26 (d, 1H, J = 3.6 Hz), 4.02 (q, 2H, J = 7.0 Hz), 3.87–3.83
(m, 1H), 3.48–3.42 (m, 1H), 3.33 (s, 1H), 2.49 (s, 3H), 2.09 (t, 2H, J = 7.2 Hz), 1.48–1.29 (m,
6H), 1.10 (t, 3H, J = 7.1 Hz); MS (API-ES) m/z (rel. intensity) 402.1 (MH+, 100); purity
determined by LC–UV at 254 nm: 94.9%.
3.1.2. Synthesis of MAL2-39—Benzyl acetoacetate (248 μL, 1.43 mmol) and para-
anisaldehyde (175 μL, 1.43 mmol) were added to a solution of butylurea acid (200 mg, 1.72
mmol) in THF (3 mL). The solution was stirred for 10 min followed by the addition of
concentrated HCl (two drops) and the resulting solution was stirred at ambient temperature for
48 h. The reaction mixture was concentrated to an oil, which was then purified by
chromatography on SiO2 with hexane/EtOAc (2:1) and eluted with CHCl3 to afford UP-
CMLD00WMAL2-39 (502.9 mg, 86%). 1H NMR (300 MHz, CDCl3) δ 7.22–7.17 (m, 3H),
7.08–7-05 (m, 2H), 7.01 (dd, 2H, J = 8.7, 2.0 Hz), 6.69 (dd, 2H, J = 8.8, 2.1 Hz), 5.40 (d, 1H,
J = 2.7 Hz), 5.22 (d, 1H, J = 2.7 Hz), 4.98 (d, 2H, J = 2.6 Hz), 3.82–3.75 (m, 1H), 3.70 (s, 3H),
3.53–3.47 (m, 1H), 2.45 (s, 3H), 1.49–1.43 (m, 2H), 1.26–1.19 (m, 2H), 0.84 (t, 3H, J = 7.2
Hz); MS (API-ES) m/z (rel. intensity) 409.1 (MH+, 100); purity determined by LC–UV at 254
nm: 92.2%.
3.1.3. Synthesis of MAL2-61—Ethyl acetoacetate (141 μL, 1.11 mmol) and 2-
formylphenyl-2-nitrobenzenesulfonate (341 mg, 1.11 mmol) were added to a solution of
benzylurea acid (200 mg, 1.33 mmol) in THF (3 mL). The solution was stirred for 10 min
followed by the addition of concentrated HCl (two drops) and the resulting solution was stirred
at ambient temperature for 48 h. The reaction mixture was concentrated to a viscous oil, which
was then purified by chromatography on SiO2 and eluted with hexane/EtOAc (2:1) to afford
UP-CMLD00WMAL2-61 (488.3 mg, 80%) as a fine solid. 1H NMR (300 MHz, CDCl3) δ 8.07
(d, 1H, J = 7.5 Hz), 7.96–7.88 (m, 2H), 7.78 (ddd, 1H, J = 14.6, 7.2, 2.2 Hz), 7.39–7.17 (m,
8H), 6.97 (dd, 1H, J = 7.1, 2.2 Hz), 5.90 (s, 2H), 5.22 (d, 1H, J = 16.3 Hz), 4.94 (d, 1H, J =
16.3 Hz), 4.00–3.90 (m, 2H), 2.56 (s, 3H), 1.04 (t, 3H, J = 7.1 Hz); 13C NMR (300 MHz,
CDCl3) δ 165.5, 152.7, 150.4, 148.7, 145.5, 137.9, 137.2, 135.8, 132.3, 132.1, 129.2, 129.1,
128.7, 128.6, 128.4, 127.4, 126.7, 125.2, 122.3, 102.8, 60.2, 48.3, 45.9, 16.3, 13.6; MS (API-
ES) m/z (rel. intensity) 552.2 (MH+, 100); purity determined by LC–UV at 254 nm: 83.8%.
3.1.4. Synthesis of MAL2-213—A stirred solution of dihydropyrimidinone (20 mg, 0.051
mmol) in CH2Cl2 (1 mL) containing DMAP (10 mg, 0.082 mmol) was treated with EDCI (11
mg, 0.056 mmol) followed by methyl 1-(2-aminoethyl)- 2-methyl-5-phenyl-1H-pyrrole-3-
carboxylate (15 mg, 0.051 mmol). The resulting solution was stirred/shaken at room
temperature for 18 h. The mixture was washed with water, dried over MgSO4, and then purified
by chromatography on SiO2 and eluted with hexane/EtOAc (3:1) and CH3Cl/EtOAc (6:1) to
afford UPCMLD00WMAL2-213 (26 mg, 81%). 1H NMR (300 MHz, CDCl3) δ 8.18 (d, 2H,
J = 6.8 Hz), 7.45–7.34 (m, 7H), 6.55 (s, 1H), 5.74 (br s, 1H), 5.54 (br s, 1H), 5.47 (d, 1H, J =
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3.1 Hz), 4.16–4.09 (m, 4H), 3.80 (s, 3H), 3.79–3.73 (m, 1H), 3.63–3.60 (m, 1H), 3.30–3.23
(m, 2H), 2.62 (s, 3H), 2.55 (s, 3H), 1.99 (t, 2H, J = 6.5 Hz), 1.83–1.72 (m, 2H), 1.20 (t, 3H,
J = 7.1 Hz); MS (APCI) m/z (rel. intensity) 1285 (2MNa+, 60), 686 (100), 664 (40), 654
(MNa+, 40), 632 (MH+, 10); purity determined by 1H NMR: >95%.
3.1.5. Synthesis of JAB75—In the presence of polyphosphate ester (PPE, 300.0 mg), a
solution of methyl 3-oxo-4-phenylbutanoate (384.0 mg, 2.0 mmol), 2-naphthaldehyde (312.0
mg, 2,0 mmol) and urea (180.0 mg, 3.0 mmol) in THF (40 mL) was heated at reflux for 15 h.
The product was extracted into EtOAc, and the combined EtOAc extracts were dried
(Na2SO4), concentrated, and purified by chromatography on SiO2 with hexane/EtOAc (3:1)
to afford 330 mg (44%) of UP-CMLD00WJAB75. 1H NMR (300 MHz, DMSO-d6) δ 9.43 (s,
1H), 7.91–7.75 (m, 4H), 7.58–7.24 (m, 8H), 5.35 (d, 1H, J = 3.3 Hz), 4.12, 4.08 (AB, 2H, J =
13.7 Hz), 3.52 (s, 3H); MS (API-ES) m/z (rel. intensity) 373 ([M+H]+, 100), 395 ([M+Na]+,
15); HRMS (EI) m/z calcd for C23H20N2O3 372.1474, found 372.1477; purity determined by
LC–UV at 254 nm: 95%.
3.2. Protein purifications
The yeast Hsp70, Ssa1, and a J domain-containing Hlj1-glutathi-one-S-transferase protein
chimera were purified as previously described. 26,32 Ydj1 was kindly provided by Dr. D. Cyr
(University of North Carolina School of Medicine), and Hdj1 was purchased from StressGen/
Assay Designs. The purification of a hexahistidine-tagged version of P. falciparum Hsp70
(PF08_0054) was performed as described33 with several modifications. The plasmid pQE30-
P. falciparum Hsp70 was introduced into chemically competent Escherichia coli Rosetta 2
cells (Novagen), and transformed colonies were selected on LB with ampicillin and
chloramphenicol. Over-night cultures were grown at 26 °C and diluted 1:10 into 1 L of the
same media, the cells were grown to mid-log phase, and IPTG was added before growth was
continued for another 5 h at 26 °C. Cells were harvested and lysed, and the extract was loaded
on a nickel-chelating Sepharose column in lysis buffer (8 M urea, 300 mM NaCl, 10 mM Tris,
pH 8.0, 10 mM imidazole, 1 mM PMSF, 2 mM leupeptin, 0.7 mM pepstatin A). The column
was washed with 10 mL of low imidazole buffer (10 mM Tris, pH 8.0, containing 300 mM
NaCl and 10 mM imidazole), followed by 20 mM imidazole buffer, and the bound proteins
were eluted using a 10 mL × 10 mL linear gradient of 25 mM to 500 mM imidazole. Samples
from 1 mL fractions were analyzed by SDS–PAGE and peak fractions were pooled and dialyzed
against 50 mM Tris, pH 7.4, containing 50 mM NaCl, 0.8 mM DTT, 2 mM MgCl2, and 5%
glycerol. The dialysate was then loaded onto a Q-Sepharose column and washed, and the
purified protein was eluted with 50 mM Tris, pH 7.4, containing 200 mM NaCl, 0.8 mM DTT,
2 mM MgCl2, and 5% glycerol. Peak fractions were identified and were dialyzed as above.
Protein aliquots were frozen in liquid nitrogen and stored at −80 °C. The activity of the enzyme
was comparable to that isolated using previously described methods.33
Human Hsp70 (HSPA1A) was purified in one of two manners. First, an untagged version was
purified based on a protocol provided by R. Morimoto (Northwestern University). A 25 mL
culture of E. coli containing plasmid pMSHSP BL21 FS in LB-ampicillin was used to inoculate
a 1 L culture, and after 4 h at 37 °C protein expression was induced with IPTG. After another
6 h, the cells were harvested and washed, and the pellet was frozen in 50 mL of TEK50 buffer
(20 mM Tris, pH 8.0, containing 0.1 mM EDTA and 50 mM KCl). The thawed pellets were
resuspended in TEK50 containing 1 mg/ml lysozyme, 0.5 mM PMSF, 1 μg/ml leupeptin, and
1 μg/ml pepstatin A, and the cells were subjected to three freeze-thaw cycles and lysed by
sonication. Cell debris was removed by low-speed centrifugation, and the supernatant was
cleared by ultracentrifugation and chromatographed on a DEAE column (Sigma-Aldrich)
equilibrated with TMC50 buffer (20 mM Tris, pH 7.2, containing 5 mM MgCl2 and 50 mM
NaCl). Bound proteins were eluted with a step gradient of TMC50 and TMC100 (20 mM Tris,
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pH 7.2, containing 5 mM MgCl2 and 100 mM NaCl), and fractions containing Hsp70, as
assessed by SDS-PAGE, were pooled and loaded onto an ATP-agarose column (Sigma-
Aldrich), which was recirculated for 4 h. The column was washed with TMC100 and the bound
Hsp70 was eluted with TMC100 containing 10% glycerol and 25 mM ATP, and then
TMC100 containing glycerol, ATP, and 4 M NaCl. Fractions containing the majority of the
Hsp70 protein, as assessed above, were pooled and dialyzed against 20 mM Tris, pH 7.2,
containing 50 mM NaCl and 1 mM EDTA. The final dialysate was loaded onto a Q-Sepharose
column (Sigma–Aldrich) equilibrated with TMC100, and the column was washed with
TMC100 and the purified Hsp70 was eluted using a linear gradient of TMC100 to TMC400. The
purified Hsp70 was dialyzed against 50 mM Tris, pH 7.4, containing 50 mM NaCl, 0.8 mM
DTT, 2 mM MgCl2, and 5% glycerol, snap-frozen in liquid nitrogen, and stored at −80 °C.
Second, a hexastidine (His6)-tagged form of human Hsp70 was constructed and purified, and
significantly higher yields of protein were obtained. To this end, plasmid DNA pMSHSP (see
above) was used as template in a polymerase chain reaction using oligonucleotide primers with
the following sequences: ACGATCGAAGAAGTGG ACCACCATCACCATCACCATTAG
(forward) and GTCCACTTCTTCGA TCGTGGGGCCTGACCCAGACCCTCC (reverse),
which replaced the six C-terminal amino acids with a His6 polypeptide tag at the C-terminus
of the Hsp70 protein coding sequence. A ligation-independent mutagenesis protocol was used
to design these primers and carry out the mutagenesis cloning.34 The sequence of the protein
coding region of the recombinant plasmid was confirmed by DNA sequencing. For expression
of recombinant Hsp70–His6, E. coli cultures containing the recombinant plasmid (pMSHSP-
His6) were grown in LB containing 100 μg/ml ampicillin to O.D.600 = 0.8 at 37 °C, and induced
at 25 °C for 18 h with 0.4 mM IPTG. Following centrifugation, the cell pellets were lysed by
a combination of sonication (model W-220F, Branson) and passing the cells through a
pressurized cell disruptor (Microfluidics) in 50 mM Tris, pH 8.0, containing 500 mM NaCl,
10% glycerol, and 20 mM imidazole. The Hsp70 was then purified at 4 °C using a standard
purification protocol recommended for use with Ni-NTA resin (QIAGEN), and the
recombinant Hsp70–His6 was eluted from the resin with 100 mM Tris, pH 8.0, containing 200
mM imidazole and 500 mM NaCl,. Next, the protein was further purified by size exclusion
chromatography using a preparative Superdex-200 gel filtration column equilibrated in 50 mM
Tris, pH 8.0, containing 500 mM NaCl. Fractions containing the purified protein were dialyzed
over-night in 10 mm Tris, pH 8.0, at 4 °C, and the dialyzed protein was pooled, aliquoted, and
stored at −70 °C.
3.3. In vitro and cell-based assays
Steady state and single turnover ATPase assays with the indicated Hsp70 preparations were
performed as previously described.18,19
Compounds were assessed for their ability to inhibit the growth of P. falciparum asexual blood
stages using [3H]hypoxanthine up-take assays, involving exposure of parasites to drug for 72
h and adding [3H]hypoxanthine for the last 24 h, as previously described. 35 Each compound
was screened at final concentrations of 1 μM and 5 μM. Compounds that initially appeared to
inhibit [3H]hypoxanthine uptake by >50% at 5 μM and displayed at least as much inhibition
at 1 μM were selected and re-screened. The group of nine compounds that passed this second
test (Fig. 2) was then subjected to dose-response analyses. IC50 values were calculated using
a linear regression analysis based on the linear portions of plotted values. The IC50 value for
CQ was assessed as described.23
The effect of the compounds on the growth of HepG2 and WI-38 cells was assessed as
previously described.18 Data are reported as GI50 values and were calculated relative to a
DMSO (negative) control.
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Figure 1.
JAB75 inhibits [3H]hypoxanthine uptake into red blood cells infected with P. falciparum. The
uptake of [3H]hypoxanthine into infected human erythrocytes and the IC50 value were
determined as described in Section 3. The raw data from a single assay were standardized such
that the inhibition of uptake in the absence of JAB75 was set to 0%.
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Figure 2.
Select pyrimidinones inhibit hypoxanthine uptake into P. falciparum-infected red blood cells.
The depicted compounds inhibited P. falciparum replication with IC50 values of 30 nM–1.6
μM (see Table 1). The structures were drawn to maximize chemical similarity.
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Figure 3.
Purification and analysis of P. falciparum Hsp70. (A) A Coomassie Brilliant blue-stained gel
summarizing individual steps during the P. falciparum Hsp70 purification is shown: lane 1:
crude E. coli lysate from the P. falciparum Hsp70 over-expressing strain; lane 2: pooled peak
fractions after nickel-affinity resin chromatography; lane 3: pooled peak fractions after Q-
sepharose column chromatography. The positions of molecular weight markers (×10−3) are
indicated to the left. Densitometry analysis indicates >95% purity. (B) The single-turnover
ATPase activity of P. falciparum Hsp70 is stimulated by a J domain-containing hybrid protein.
ATPase assays were performed as described in Section 3 in the presence of 3 μg of the Hlj1
chimeric protein. Data represent the means of 6 independent determinations, ±SD.
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Table 1
Effects of most potent P. falciparum inhibitors on the steady-state ATPase activities of P. falciparum, yeast
(Ssa1), and human (HsHsp70)
Compound P. falciparum IC50 (μM) PfHsp70 (ATPase) Ssal (ATPase) HsHsp70 (ATPase)
DMSO 1 1 1
DMT3024 0.2 0.73 ± 0.003 1.0 ± 0.004 0.74 ± 0.003
DMT2264 1.1 0.74 ± 0.002 0.97 ± 0.004 0.95 ± 0.002
MAL2-29 1.6 1.01 ± 0.1 0.93 ± 0.007 0.85 ± 0.06
MAL2-39 0.2 0.92 ± 0.05 0.95 ± 0.004 0.80 ± 0.08
MAL2-61 0.1 0.99 ± 0.07 1.1 ± 0.003 0.74 ± 0.07
MAL2-213 0.03 1.02 ± 0.11 0.89 ± 0.016 0.80 ± 0.06
MAL2-215 0.05 1.01 ± 0.08 1.2 0.72 ± 0.09
MAL3-39 0.8 0.72 ± 0.08 0.75 0.82 ± 0.05
JAB75 0.3 1.0 ± 0.06 1.2 0.70 ± 0.06
The IC50 value for inhibition of [3H]hypoxanthine uptake is shown in the second column. The three columns on the right depict the relative activities of
each enzyme (after standardization to the activity with an equal volume of DMSO, which was set to ‘1’) in the presence of a final concentration of 300
μM of the designated compound. The turnover numbers of each enzyme in the presence of DMSO were: P. falciparum Hsp70: 0.020 min−1; Ssa1: 0.032
min−1; HsHsp70: 0.025 min−1. Stained gels showing the enriched proteins used in this analysis are provided in a Supplementary Figure (Fig. S1). Data
represent the means of 6 independent experiments, and where shown, ±SD.
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